相关实验视频
Updated: Jul 16, 2025

08:05
Assaying Protein Kinase Activity with Radiolabeled ATP
Published on: May 26, 2017
18.4K
通过动态S-化来调节ERK2活动
Saara-Anne Azizi1, Tian Qiu2, Noah E Brookes2
1Department of Chemistry, The University of Chicago, Chicago, IL 60637, USA; Medical Scientist Training Program, Pritzker School of Medicine, The University of Chicago, Chicago, IL 60637, USA.
Cell reports
|September 16, 2023
概括
细胞外信号调节激酶 (ERK1/2) 通过S-化,一种可逆的脂质修饰,获得新的调节层. 这种脂化影响ERK1/2信号传递,与代谢综合征有关,提供了新的治疗点.
科学领域:
- 细胞生物学 细胞生物学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 细胞外信号调节激酶 (ERK1/2) 是细胞过程的关键调节者,在线素激活蛋白激酶通路内.
- 了解管理ERK1/2活动的翻译后修改对于破译复杂的细胞信号网络至关重要.
研究的目的:
- 通过S-化来研究ERK1/2的新型调节机制.
- 探索ERK1/2 S-化对信号通路和细胞反应的功能影响.
- 为了确定ERK1/2脂化和代谢综合征之间的联系.
主要方法:
- 在ERK1/2 (C271/C254) 上S-化位点的识别和表征.
- 针对表皮生长因子 (EGF) 信号的ERK1/2 S-化动态的分析.
- 研究蛋白乙烯转移酶 (PAT) 和乙烯蛋白化酶 (APT) 在调节ERK1/2 S-化中的作用.
- 对抑制S-化机制对EGF触发的转录程序的影响的评估.
- 在代谢综合征的小鼠模型中,对ERK1/2脂化水平与写/擦表达的相关性分析.
主要成果:
- 在ERK1/2蛋白中,在氨酸残留物C271/C254.4处进行S-化.
- ERK1/2 S-化水平由EGF信号动态调节,反映了酸化模式.
- 缺氧化ERK2表现出改变的酸化动态.
- 抑制S-化"写字器" (PATs) 或"消光器" (APTs) 改变了ERK1/2对EGF的转录反应.
- 在代谢综合征模型中,ERK1/2脂化与其修饰酶的改变表达相关,将脂化与生物体健康联系起来.
结论:
- S-化是一种新的,动态的翻译后修饰,控制ERK1/2活动和信号.
- S-化和化之间的相互作用微调细胞对生长因子刺激的反应.
- ERK1/2 S-化失调与代谢综合征有关,突出了其作为治疗点的潜力.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
Regulation of the Unfolded Protein Response
2.5K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.5K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K

